

GLAXOSMITHKLINE PLC
Form 6-K
February 20, 2009

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending February, 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors and Persons Discharging Managerial Responsibility

I give below details of changes in the interests of
:

- Directors and Persons Discharging Managerial Responsibility in the Ordinary shares of GlaxoSmithKline plc in respect of the under mentioned persons arising from the sale of Ordinary shares at a price of £11.91 per Ordinary Share on 19 February 2009 to meet their tax liabilities following the vesting of a Performance Share Plan (PSP) award
:

No
 .
of Ordinary
s
shares sold to meet tax liabilities following the vesting of a PSP award

Dr M M Slaoui*	6,188
Mr S M Bicknell	1,293
Mr E J Gray	2,738
Mr D Learmouth	1,293
Ms C Thomas	2,060
Mr D S Redfern	2,738

* Denotes an Executive Director

- Persons

Discharging Managerial Responsibility in the
American Depositary Shares (ADSs)
of GlaxoSmithKline plc in respect of the under mentioned
persons
arising from the
withholding of shares
at a price of
\$33.42

per
ADS
on
19

February 2009

to meet their tax liabilities following the vesting of a Performance Share Plan award
:

No

**.
of
ADSs**

**withheld
to meet tax liabilities following the vesting of a PSP award**

Mr W C Louv

990

* Denotes an Executive Director

The Company, Directors, Persons Discharging Managerial Responsibility were advised of these
transactions on
20 February 2009
.

This notification relates to a transaction notified in accordance with

Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Deputy
Company Secretary

20 February 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: February 20, 2009

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc